Evofem Biosciences (Evofem Biosciences) Change In Receivables : $3.10 Mil (TTM As of Mar. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Evofem Biosciences Change In Receivables?

Evofem Biosciences's change in receivables for the quarter that ended in Mar. 2024 was $1.43 Mil. It means Evofem Biosciences's Accounts Receivable declined by $1.43 Mil from Dec. 2023 to Mar. 2024 .

Evofem Biosciences's change in receivables for the fiscal year that ended in Dec. 2023 was $-4.61 Mil. It means Evofem Biosciences's Accounts Receivable increased by $4.61 Mil from Dec. 2022 to Dec. 2023 .

Evofem Biosciences's Accounts Receivable for the quarter that ended in Mar. 2024 was $4.31 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Evofem Biosciences's Days Sales Outstanding for the three months ended in Mar. 2024 was 109.05.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Evofem Biosciences's liquidation value for the three months ended in Mar. 2024 was $-75.00 Mil.

Evofem Biosciences Change In Receivables Historical Data

The historical data trend for Evofem Biosciences's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Evofem Biosciences Change In Receivables Chart

Evofem Biosciences Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Receivables

Get a 7-Day Free Trial

-1.07

-5.38

5.32

-4.61

Evofem Biosciences Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Change In Receivables	Get a 7-Day Free Trial															-6.28	2.21	-1.12	0.58	1.43

Evofem Biosciences Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $3.10 Mil.

Evofem Biosciences (OTCPK:EVFM) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Evofem Biosciences's Days Sales Outstanding for the quarter that ended in Mar. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	4.306	/	3.603	*	91
=	109.05

2. In Ben Graham's calculation of liquidation value, Evofem Biosciences's accounts receivable are only considered to be worth 75% of book value:

Evofem Biosciences's liquidation value for the quarter that ended in Mar. 2024 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	0	-	78.883	+	0.75 * 4.306	+	0.5 * 1.306
=	-75.00

Evofem Biosciences Change In Receivables Related Terms

Thank you for viewing the detailed overview of Evofem Biosciences's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Evofem Biosciences (Evofem Biosciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Evofem Biosciences Inc (OTCPK:EVFM) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

N/A

Address

7770 Regents Road, Suite 113-618, San Diego, CA, USA, 92122

Website

https://www.evofem.com

Evofem Biosciences Inc is a commercial-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health. The company's product, Phexxi (lactic acid, citric acid and potassium bitartrate), is a hormone-free, prescription vaginal gel approved in the United States for the prevention of pregnancy.

Executives

Yan Zhang	officer: Chief Financial Officer	6166 TIKI CT, SAN DIEGO CA 92130
Kim P. Kamdar	director, 10 percent owner	C/O DOMAIN ASSOCIATES, L.L.C., ONE PALMER SQUARE, SUITE 515, PRINCETON NJ 08542
Jenny C. Yip	director	12400 HIGH BLUFF DR., STE. 600, SAN DIEGO CA 92130
Atkinson Katherine Cocca	officer: Chief Commercial Officer	12400 HIGH BLUFF., STE. 600, SAN DIEGO CA 92130
Saundra L Pelletier	director, officer: Chief Executive Officer	C/O EVOFEM BIOSCIENCES, INC., 12400 HIGH BLUFF DRIVE, SUITE 600, SAN DIEGO CA 92130
Alexander A Fitzpatrick	officer: General Counsel and Secretary	9605 SCRANTON ROAD, SUITE 200, SAN DIEGO CA 92121
Justin J. File	officer: Chief Financial Officer	C/O EVOFEM BIOSCIENCES, INC., 12400 HIGH BLUFF DRIVE, SUITE 600, SAN DIEGO CA 92130
Anthony Stephen O'brien	director	C/O EVOFEM BIOSCIENCES, INC., 12400 HIGH BLUFF DRIVE, SUITE 600, SAN DIEGO CA 92130
Russell Barrans	officer: Chief Commercial Officer	C/O EVOFEM BIOSCIENCES, INC., 12400 HIGH BLUFF DRIVE, SUITE 600, SAN DIEGO CA 92130
Lisa Dale Rarick	director	C/O EVOFEM BIOSCIENCES, INC., 12400 HIGH BLUFF DRIVE, STE 600, SAN DIEGO CA 92130
William Walmsley Hall	director	C/O EVOFEM BIOSCIENCES, INC., 12400 HIGH BLUFF DIRVE, SUITE 600, SAN DIEGO CA 92130
Invesco Ltd.	10 percent owner	1331 SPRING STREET NW, SUITE 2500, ATLANTA GA 30309
Link Fund Solutions Ltd	10 percent owner	65 GRESHAM STREET, LONDON X0 EC2V 7NQ
Acacia Research Corp	10 percent owner	767 3RD AVENUE, 6TH FLOOR, NEW YORK NY 10017
Kelly Culwell	officer: Chief Medical Officer	C/O EVOFEM BIOSCIENCES, INC., 12400 HIGH BLUFF DRIVE, SUITE 600, SAN DIEGO CA 92130